KR101617811B1 - 지질조성 - Google Patents

지질조성 Download PDF

Info

Publication number
KR101617811B1
KR101617811B1 KR1020107025087A KR20107025087A KR101617811B1 KR 101617811 B1 KR101617811 B1 KR 101617811B1 KR 1020107025087 A KR1020107025087 A KR 1020107025087A KR 20107025087 A KR20107025087 A KR 20107025087A KR 101617811 B1 KR101617811 B1 KR 101617811B1
Authority
KR
South Korea
Prior art keywords
delete delete
testosterone
composition
lipid
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107025087A
Other languages
English (en)
Korean (ko)
Other versions
KR20110007169A (ko
Inventor
히엡 후아탄
리차드 로스
Original Assignee
다이어널 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이어널 리미티드 filed Critical 다이어널 리미티드
Publication of KR20110007169A publication Critical patent/KR20110007169A/ko
Application granted granted Critical
Publication of KR101617811B1 publication Critical patent/KR101617811B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107025087A 2008-04-28 2009-04-27 지질조성 Active KR101617811B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0807605.1A GB0807605D0 (en) 2008-04-28 2008-04-28 Lipid composition
GB0807605.1 2008-04-28

Publications (2)

Publication Number Publication Date
KR20110007169A KR20110007169A (ko) 2011-01-21
KR101617811B1 true KR101617811B1 (ko) 2016-05-03

Family

ID=39522593

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107025087A Active KR101617811B1 (ko) 2008-04-28 2009-04-27 지질조성

Country Status (15)

Country Link
US (2) US9012436B2 (enExample)
EP (2) EP2722038A3 (enExample)
JP (1) JP5727925B2 (enExample)
KR (1) KR101617811B1 (enExample)
CN (1) CN102083421B (enExample)
AU (1) AU2009241910B2 (enExample)
CA (1) CA2722408C (enExample)
DK (1) DK2273984T3 (enExample)
ES (1) ES2502242T3 (enExample)
GB (1) GB0807605D0 (enExample)
IL (2) IL208612A (enExample)
PL (1) PL2273984T3 (enExample)
PT (1) PT2273984E (enExample)
WO (1) WO2009133352A2 (enExample)
ZA (1) ZA201007612B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
ES2930658T3 (es) 2005-04-15 2022-12-20 Tolmar Inc Sistemas de administración farmacéutica para medicamentos hidrofóbicos y composiciones que comprenden los mismos
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
WO2009114365A2 (en) * 2008-03-13 2009-09-17 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
MX363561B (es) * 2011-05-15 2019-03-27 Trimel Biopharma Srl Geles nasales de liberacion controlada de testosterona, metodos y sistemas aplicadores multidosis pre cargados para administracion pernasal.
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US20140179655A1 (en) 2012-12-20 2014-06-26 Solural Pharma ApS Solid oral dosage form of testosterone derivative
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US9889108B2 (en) 2013-03-15 2018-02-13 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
KR101440726B1 (ko) * 2013-04-16 2014-09-18 중앙대학교 산학협력단 가용화제를 포함하는 림프계 약물전달 시스템용 조성물
EP3054940B1 (en) * 2013-10-07 2020-09-23 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US11197828B2 (en) 2014-06-19 2021-12-14 Solural Pharma ApS Solid oral dosage form of lipophilic compounds
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
EP3185872B1 (en) * 2014-08-28 2021-03-31 Board of Regents, The University of Texas System Formulations of testosterone and methods of treatment therewith
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR101679380B1 (ko) * 2015-09-10 2016-11-25 주식회사 유유제약 두타스테리드를 포함하는 약학적 조성물 및 이를 포함하는 캡슐 제형
CN106562949A (zh) * 2015-10-10 2017-04-19 浙江旭晨医药科技有限公司 甘油三酯类化合物在制备治疗多囊卵巢综合征药物中的应用
KR102351762B1 (ko) * 2016-03-02 2022-01-18 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 테스토스테론 제형 및 이를 이용한 치료 방법
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2019046582A1 (en) * 2017-08-30 2019-03-07 Antares Pharma, Inc. TESTOSTERONE ESTER TRIGLYCERIDE FORMULATIONS
US11311554B2 (en) * 2018-04-04 2022-04-26 Slayback Pharma Llc Pharmaceutical compositions of testosterone
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
CN114617968B (zh) * 2019-04-09 2023-10-03 北京五和博澳药业股份有限公司 黄酮多酚类药物自乳化组合物、其制备方法、药物组合物及用途
AU2021216630A1 (en) 2020-02-05 2022-09-22 Neurocrine UK Limited Testosterone containing pharmaceutical composition
WO2024014958A2 (en) * 2022-07-15 2024-01-18 Seranovo Holding B.V. Lides formulation platform
WO2024014959A2 (en) * 2022-07-15 2024-01-18 Seranovo Holding B.V. Micelle-generating formulations with improved hydrophobicity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526620A (ja) * 1999-04-01 2003-09-09 アール．ピー． シェーラー コーポレイション 長鎖トリグリセリドと親油性界面活性剤とを含有する経口医薬組成物
US20050043285A1 (en) 2000-01-10 2005-02-24 Astrazeneca Ab Formulation
WO2005076899A2 (en) * 2004-02-09 2005-08-25 University Of Washington Oral androgen therapy using modulators of testosterone bioavailablity
EP1743646A2 (en) 2003-03-14 2007-01-17 Schering Aktiengesellschaft Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098802A (en) * 1975-02-18 1978-07-04 Akzona Incorporated Oral pharmaceutical preparation having androgenic activity
GB1567515A (en) 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
US6541025B1 (en) 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
ES2930658T3 (es) 2005-04-15 2022-12-20 Tolmar Inc Sistemas de administración farmacéutica para medicamentos hidrofóbicos y composiciones que comprenden los mismos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003526620A (ja) * 1999-04-01 2003-09-09 アール．ピー． シェーラー コーポレイション 長鎖トリグリセリドと親油性界面活性剤とを含有する経口医薬組成物
US20050043285A1 (en) 2000-01-10 2005-02-24 Astrazeneca Ab Formulation
EP1743646A2 (en) 2003-03-14 2007-01-17 Schering Aktiengesellschaft Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
WO2005076899A2 (en) * 2004-02-09 2005-08-25 University Of Washington Oral androgen therapy using modulators of testosterone bioavailablity

Also Published As

Publication number Publication date
EP2722038A3 (en) 2014-06-18
EP2273984B1 (en) 2014-07-30
PT2273984E (pt) 2014-11-03
ZA201007612B (en) 2011-07-27
EP2722038A2 (en) 2014-04-23
PL2273984T3 (pl) 2015-04-30
WO2009133352A3 (en) 2010-10-28
ES2502242T3 (es) 2014-10-03
WO2009133352A2 (en) 2009-11-05
CN102083421B (zh) 2012-12-12
KR20110007169A (ko) 2011-01-21
US9012436B2 (en) 2015-04-21
US20150133417A1 (en) 2015-05-14
EP2273984A2 (en) 2011-01-19
US20110039814A1 (en) 2011-02-17
IL236400A0 (en) 2015-01-29
IL236400A (en) 2016-06-30
GB0807605D0 (en) 2008-06-04
CA2722408C (en) 2018-01-30
IL208612A (en) 2015-03-31
DK2273984T3 (da) 2014-08-25
JP2011519846A (ja) 2011-07-14
CN102083421A (zh) 2011-06-01
IL208612A0 (en) 2010-12-30
CA2722408A1 (en) 2009-11-05
JP5727925B2 (ja) 2015-06-03
AU2009241910A1 (en) 2009-11-05
AU2009241910B2 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
KR101617811B1 (ko) 지질조성
JP5992397B2 (ja) 経口テストステロンエステル配合剤およびそれを含むテストステロン欠損を処置する方法
EP2519230B1 (en) Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
RU2429850C2 (ru) Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
EP0904064B1 (en) Oral pharmaceutical compositions containing sex hormones
CN1809339B (zh) 用于出生后荷尔蒙替代品的油乳状液
US20120135074A1 (en) High-Strength Testosterone Undecanoate Compositions
US20190282698A1 (en) Steroid hormone compositions in medium chain oils
CN105188670B (zh) 乳液制剂
US11433083B2 (en) High-strength testosterone undecanoate compositions
CN105073118A (zh) 用于经口递送的脂平衡长链睾酮酯
AU2014200332B2 (en) Lipid composition
HK1194006A (en) Lipid composition
JP6097803B2 (ja) 経口テストステロンエステル配合剤およびそれを含むテストステロン欠損を処置する方法
US20250319101A1 (en) Oral pharmaceutical compositions of progesterone and estradiol
RU2642244C2 (ru) Оральные фармацевтические композиции сложных эфиров тестостерона и способы лечения недостатка тестостерона с их использованием
JP5815900B2 (ja) 経口テストステロンエステル配合剤およびそれを含むテストステロン欠損を処置する方法
HK1219061B (zh) 乳液制剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101108

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140402

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150813

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160204

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160427

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160428

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190328

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190328

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210329

Start annual number: 6

End annual number: 6